About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Sesen Bio, Inc. (SESN) Investors

By: via Business Wire

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Sesen Bio, Inc. (“Sesen Bio” or the “Company”) (NASDAQ: SESN) securities from December 21, 2020 through August 17, 2021, inclusive (the “Class Period”). Investors have until October 18, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Sesen Bio, a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (“TFPTs”) for the treatment patients with cancer. The Company’s most advanced product candidate is Vicinieum, a locally-administered targeted fusion protein developed as a treatment of BCG-unresponsive non-muscle invasive bladder cancer (“NMIBC”).

On August 13, 2021, Sesen Bio announced that the U.S. Food and Drug Administration (“FDA”) declined to approve its Biologics License Application for its bladder cancer treatment Vicineum its current form. The FDA provided certain “recommendations specific to additional clinical/statistical data and analyses in addition to Chemistry, Manufacturing and Controls (“CMC”) issues pertaining to a recent pre-approval inspection and product quality.” On this news, the Company’s share price declined by $2.80 per share, or approximately 57%, to close at $2.11 per share on August 13, 2021.

Then, on August 16, 2021, Sesen Bio further revealed that it appears that [the Company] will need to do a clinical trial to provide the additional efficacy and safety data necessary for the FDA to assess the benefit-risk profile, which is the basis for approval. As a result, the Company expected that it could not resubmit its BLA until 2023. On this news, the Company’s share price declined by $0.89 per share, or approximately 42%, to close at $1.22 per share on August 16, 2021.

Then, on August 18, 2021, before the market opened, the health and medicine news site STAT published an article entitled Sesen Bio trial of cancer drug marked by misconduct and worrisome side effects, documents show. Citing hundreds of pages of internal documents and three people familiar with the matter, the article detailed that the clinical trial for Vicineum was marked by thousands of violations of study rules, damning investigator conduct, and worrying signs of toxicity the Company did not publicly disclose. On this news, the Company’s share price declined by $0.20 per share, or 13%, to close at $1.31 per share on August 18, 2021.

The lawsuit alleges throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Sesen Bio’s clinical trial for Vicineum had more than 2,000 violations of trial protocol, including 215 classified as major; (2) that three of Sesen Bio’s clinical investigators were found guilty of serious noncompliance, including back-dating data; (3) that Sesen Bio had submitted the tainted data in connection with the BLA for Vicineum; (4) that Sesen Bio’s clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) that, as a result of the foregoing, the Company’s BLA for Vicineum was not likely to be approved; (6) that, as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) that, as a result of the foregoing, Defendants positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired Sesen Bio securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

More News

View More
Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why
Via MarketBeat
Topics Artificial Intelligence
Tickers AMZN CRM GOOGL META MSFT ORCL
General Mills Is a Generational Opportunity for Income Investors
Via MarketBeat
Tickers GIS
DoorDash Buys Deliveroo: A Game Changer?
Via MarketBeat
Tickers DASH
Is Netflix's Ad Deal With Amazon the Catalyst for a New Uptrend?
Via MarketBeat
Topics Government World Trade
Tickers AMZN NFLX TTD
Clearway Energy’s Price Dip: 3 Reasons It’s a Signal to Buy
Via MarketBeat
Tickers CWEN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.